一分钟看懂
这是一项关于多发性骨髓瘤的II 期研究，登记的药物或干预包括Carfilzomib；Dexamethasone；Isatuximab；Pomalidomide；Bone Marrow Biopsy；Bone Marrow Aspiration；Skeletal Survey X-Ray；Computed Tomography；Positr，当前状态为研究进行中，已停止招募。登记地点显示中国Seattle有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Carfilzomib；Dexamethasone；Isatuximab；Pomalidomide；Bone Marrow Biopsy；Bone Marrow Aspiration；Skeletal Survey X-Ray；Computed Tomography；Positron Emission Tomography；Magnetic Resonance Imaging · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Fred Hutch/University of Washington Cancer Consortium · Seattle
公开的入选条件
- * Patients with relapsed or refractory multiple myeloma, with \>= 1 prior therapy
- * Must have received prior lenalidomide therapy
- * Must have measurable disease, as defined by International Myeloma Working Group criteria, having one or more of the following:
- Serum M protein \>= 0.5 g/dL
- Urine M protein \>= 200 mg/24 hours
- Involved serum free light chain level \>= 10 mg/dL with abnormal kappa/lambda ratio
- Measurable biopsy-proven plasmacytomas (\>= 1 lesion has a single diameter \>= 2 cm)
- Bone marrow plasma cells \>= 30%
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04883242；登记信息更新于 2026-09-16。